Previous 10 | Next 10 |
HOOKIPA Pharma Inc. (HOOK) Q4 2019 Earnings Conference Call March 19, 2020, 08:00 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - CEO Reinhard Kandera - CFO Igor Matushansky - CMO Roman Necina - CTO Conference Call Participant...
HOOKIPA Pharma (NASDAQ: HOOK ): Q4 GAAP EPS of -$0.40 misses by $0.29 . More news on: HOOKIPA Pharma Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK and VIENNA, Austria, March 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its fina...
NEW YORK and VIENNA, Austria, March 10, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that i...
NEW YORK and VIENNA, Austria, Feb. 18, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HO...
Small-cap biotech stocks have consistently been one of the best-performing groups of equities for almost 10 straight years. The advent of several game-changing technologies, broader access to healthcare globally, and an aging population in the United States have all helped to boost valuations am...
NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HO...
HOOKIPA Pharma (NASDAQ: HOOK ) doses first patient in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16 + ) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology. More news on: HOO...
NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that th...
No matter how much falls on us, we keep plowing ahead. That's the only way to keep the roads clear. "― Greg Kincaid Today we take a look at a ' Tier 4 ' developmental concern that came public in the second quarter of this year. The stock has had a big rally recently but is still ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com